Here’s why Alexion Pharmaceuticals (ALXN) sky-rocketed in the pre-market session

AVGR Stock
AVGR Stock

Alexion Pharmaceuticals stocks surged 33.09% to $161.1 in the pre-market session following a report that AstraZeneca and Alexion Pharmaceuticals (ALXN) have signed a formal deal about the purchase of Alexion by AstraZeneca.

As demonstrated by American Depositary Receipts (ADRs), for each Alexion share, Alexion shareholders would earn $60 in cash and 2,1243 AstraZeneca American Depositary Shares (ADSs). This means a cumulative consideration of $39bn or $175 per share to Alexion shareholders based on AstraZeneca’s reference average ADR price of $54.14.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The boards of both companies have overwhelmingly approved the acquisition. The merger is scheduled to close in Q3 2021, subject to receipt of regulatory clearances and shareholders’ consent in both companies. Upon closure, Alexion shareholders will control approximately 15 percent of the merged business.

To produce life-changing drugs, both businesses have the same commitment to research and engineering. Both organizations’ skills will develop a business with strong strengths through many technological channels and produce revolutionary drugs for millions of people around the world. The merged business would also provide an increased geographic presence and broad reach across the core, specialty, and highly specialized care.


Please enter your comment!
Please enter your name here